Safety and immunogenicity of CpG 1018 and aluminium hydroxide-adjuvanted SARS-CoV-2 S-2P protein vaccine MVC-COV1901: interim results of a large-scale, double-blind, randomised, placebo-controlled phase 2 trial in Taiwan-Reference-Cited by-同舟云学术

Safety and immunogenicity of CpG 1018 and aluminium hydroxide-adjuvanted SARS-CoV-2 S-2P protein vaccine MVC-COV1901: interim results of a large-scale, double-blind, randomised, placebo-controlled phase 2 trial in Taiwan

Published:2021-12 Issue:12 Volume:9 Page:1396-1406
ISSN:2213-2600
Container-title:The Lancet Respiratory Medicine
language:en
Short-container-title:The Lancet Respiratory Medicine

Author:

Hsieh Szu-Min,Liu Ming-Che,Chen Yen-Hsu,Lee Wen-Sen,Hwang Shinn-Jang,Cheng Shu-Hsing,Ko Wen-Chien,Hwang Kao-Pin,Wang Ning-Chi,Lee Yu-Lin,Lin Yi-Ling,Shih Shin-Ru,Huang Chung-Guei,Liao Chun-Che,Liang Jian-Jong,Chang Chih-Shin,Chen Charles,Lien Chia En,Tai I-Chen,Lin Tzou-Yien

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine

Reference16 articles.

1. A pneumonia outbreak associated with a new coronavirus of probable bat origin;Zhou;Nature,2020

2. Development of CpG-adjuvanted stable prefusion SARS-CoV-2 spike antigen as a subunit vaccine against COVID-19;Kuo;Sci Rep,2020

3. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation;Wrapp;Science,2020

4. CpG-adjuvanted stable prefusion SARS-CoV-2 spike protein protected hamsters from SARS-CoV-2 challenge;Lien;Sci Rep,2021

5. Safety and immunogenicity of a recombinant stabilized prefusion SARS-CoV-2 spike protein vaccine (MVC-COV1901) adjuvanted with CpG 1018 and aluminium hydroxide in healthy adults: a phase 1, dose-escalation study;Hsieh;EClinicalMedicine,2021

Cited by 112 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Preparation and immunological activity evaluation of an intranasal protein subunit vaccine against ancestral and mutant SARS-CoV-2 with curdlan sulfate/O-linked quaternized chitosan nanoparticles as carrier and adjuvant;International Journal of Biological Macromolecules;2024-09

2. The Development of Epitope-Based Recombinant Protein Vaccines against SARS-CoV-2;The AAPS Journal;2024-08-13

3. Effectiveness and evolution of anti-SARS-CoV-2 spike protein titers after three doses of COVID-19 vaccination in people with HIV;Journal of Microbiology, Immunology and Infection;2024-08

4. The presence of broadly neutralizing anti-SARS-CoV-2 RBD antibodies elicited by primary series and booster dose of COVID-19 vaccine;PLOS Pathogens;2024-06-10

5. Cutaneous adverse reactions associated with COVID-19 vaccines: Current evidence and potential immune mechanisms;Clinical Immunology;2024-06